Merck & Company Inc (MRK)vsInsulet Corporation (PODD)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
PODD
Insulet Corporation
$160.02
-12.50%
HEALTHCARE · Cap: $11.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2301% more annual revenue ($65.01B vs $2.71B). MRK leads profitability with a 28.1% profit margin vs 9.1%. PODD appears more attractively valued with a PEG of 1.01. PODD earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
PODD
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
-49.6%
Fair Value
$167.73
Current Price
$160.02
$7.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Revenue surging 31.2% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
3.9% earnings growth
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : PODD
The strongest argument for PODD centers on Revenue Growth. Revenue growth of 31.2% demonstrates continued momentum. PEG of 1.01 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : PODD
The primary concerns for PODD are EPS Growth, P/E Ratio. A P/E of 46.1x leaves little room for execution misses.
Key Dynamics to Monitor
MRK profiles as a value stock while PODD is a hypergrowth play — different risk/reward profiles.
PODD carries more volatility with a beta of 1.47 — expect wider price swings.
PODD is growing revenue faster at 31.2% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 59/100), backed by strong 28.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Insulet Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?